NAICS code
Research and Development in Biotechnology (except Nanobiotechnology)
- NAICS code
- 541714
- Latest action
- Sep 24, 2026
Fewer than the minimum comparable awards under this NAICS code.
Largest awards under this code
| Award | Contractor | Agency | Place | First action | Current value |
|---|---|---|---|---|---|
| HQ014719C0004 GMD DEVELOPMENT AND SUSTAINMENT CONTRACT | THE BOEING COMPANY | Department of Defense | AL | Mar 23, 2026 | $5,018,451,126 |
| 75A50123F61004 OT TASK ORDER 4 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | SC | Sep 28, 2023 | $1,010,801,807 |
| 75A50122C00065 TREATMENT FOR USE IN A MASS CASUALTY EVENT WHERE THROMBOCYTOPENIA OR PLATELET LOSS IS A MAJOR CONCERN. | AMGEN USA INC | Department of Health and Human Services | CA | Sep 28, 2022 | $839,875,190 |
| 75A50123F61001 EOI::RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING ::EOI ADMINISTRATIVE MODIFICATION REPORTING TERMINATION OF PROJECT AGREEMENT | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | SC | Mar 12, 2026 | $795,000,000 |
| 75A50123F61003 EOI:EO: RADICAL TRANSPARENCY ABOUT WASTEFUL SPENDING::EOI DEOBLIGATION OF FUNDS AND PARTIAL DE-SCOPE | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | SC | Mar 11, 2026 | $723,524,000 |
| 75A50118C00019 PROCUREMENT AND LATE-STAGE DEVELOPMENT OF SMALLPOX ANTIVIRAL DRUG(S) IGF::OT::IGF | SIGA TECHNOLOGIES, INC. | Department of Health and Human Services | OR | Sep 10, 2018 | $626,506,870 |
| N0001924C0061 THIS MODIFICATION INCREMENTALLY FUNDS CLIN 0001. | L3 TECHNOLOGIES, INC. | Department of Defense | UT | Mar 19, 2026 | $587,386,007 |
| 75A50126C00001 STRATEGIC MARBURG ADVANCED RESEARCH AND DEVELOPMENT, PREPAREDNESS, REGISTRATION, EVALUATION AND PROCUREMENT (SMART-PREP) | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Department of Health and Human Services | DC | May 5, 2026 | $263,613,186 |
| 75A50124C00012 OTHER TRANSACTION: START2 GROUP, INC. (75A50124C00012) | START2 GROUP, INC. | Department of Health and Human Services | MA | Apr 9, 2024 | $223,139,021 |
| 75A50122C00061 PROCUREMENT OF THERAPEUTICS FOR EBOLA, SUDAN AND MARBURG VIRUSES | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | CA | Sep 27, 2022 | $220,916,162 |
| 75A50122C00047 THE PURPOSE OF THIS MODIFICATION IS TO UPDATE THE UEI FROM JLLWGQX6LNA5 TO MUM1EGCDWZJ4. | EMERGENT BIODEFENSE OPERATIONS LANSING LLC | Department of Health and Human Services | NC | Apr 21, 2026 | $213,770,068 |
| 75A50123C00010 THE PURPOSE OF THIS MODIFICATION IS TO 1. OPTION 7 (CLIN 0008): DECREASE THE VALUE FROM $6,888,289.01 BY $1,713,590.57 TO $5,174,698.44. 2. OPTION 10 (CLIN 0011): INCREASE THE VALUE FROM $1,554,748.99 BY $1,713,590.57 TO $3,268,339.56. 3. OPTION 4 | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Department of Health and Human Services | DC | May 11, 2026 | $163,082,416 |
| 75A50123F61005 THE PURPOSE OF THIS MODIFICATION IS TO: 1. CHANGE THE APPROVING OFFICIAL. | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | SC | Mar 24, 2026 | $161,082,263 |
| 75A50126C00004 LATE-STAGE DEVELOPMENT, FDA MARKETING AUTHORIZATION, PROCUREMENT, AND STOCKPILE OF ANTIBIOTICS FOR THE TREATMENT OF DRUG-RESISTANT SECONDARY BACTERIAL INFECTIONS AND/OR THE TREATMENT OR PEP OF INFECTIONS CAUSED BY BIOTHREAT PATHOGENS. | SHIONOGI INC | Department of Health and Human Services | NJ | Apr 6, 2026 | $156,103,541 |
| 75A50122C00076 THIS COST-PLUS-FIXED-FEE CONTRACT WITH MAPP BIOPHARMACEUTICAL, INC. (MAPP OR CONTRACTOR) IS FOR THE DEVELOPMENT OF MAPP?S THERAPEUTIC INTERVENTION MBP091, AS AN IMMUNOTHERAPY FOR THE TREATMENT OF MARBURG VIRUS INFECTION. | MAPP BIOPHARMACEUTICAL, INC. | Department of Health and Human Services | CA | Sep 28, 2022 | $155,212,688 |
| 75A50122C00028 CARB-X GLOBAL ANTIBACTERIAL ACCELERATOR OTA - UPDATE PERIOD OF PERFORMANCE | TRUSTEES OF BOSTON UNIVERSITY | Department of Health and Human Services | MA | Apr 28, 2026 | $150,780,000 |
| 75A50119C00055 THIS CONTRACT IS TO ADVANCE THE DEVELOPMENT OF MONOVALENT VACCINES FOR PREVENTION OF MARBURG VIRUS (MARV) AND SUDAN EBOLAVIRUS (SUDV) DISEASE. | ALBERT B. SABIN VACCINE INSTITUTE, INC. (THE) | Department of Health and Human Services | DC | Sep 26, 2019 | $145,378,689 |
| 75A50119C00007 THE PURPOSE OF THIS BILATERAL MODIFICATION DE-OBLIGATES CANCELING YEAR FUNDS FROM REQUISITION OS256610 IN THE AMOUNT OF (-$615,177.10) FROM CLIN0006 AND FROM REQUISITION OS257789 IN THE AMOUNT OF (-$222.20) FROM CLIN00001. | VENATORX PHARMACEUTICALS INC | Department of Health and Human Services | PA | May 26, 2026 | $131,756,814 |
| 75A50124C00033 THE DEVELOPMENT OF ANTIMICROBIALS FOR THE TREATMENT OF RESISTANT FUNGAL AND BACTERIAL INFECTIONS - OTA | BASILEA PHARMACEUTICA INTERNATIONAL LTD, ALLSCHWIL | Department of Health and Human Services | — | Sep 18, 2024 | $122,501,232 |
| 47QFWA20C0012 MIGRATED ID07200010 59MDW SCIENCE TECHNOLOGY START: DEOBLIGATE EXCESS FUNDS AND FINAL CONTRACT CLOSEOUT. | ABSS SOLUTIONS INC | General Services Administration | TX | May 1, 2026 | $120,718,969 |
| 75A50123F61002 OT TASK ORDER 2 | ADVANCED TECHNOLOGY INTERNATIONAL | Department of Health and Human Services | SC | Sep 28, 2023 | $120,250,000 |
| 75A50122C00031 ADVANCED RESEARCH AND DEVELOPMENT AND DELIVERY OF ADULT AND PEDIATRIC MIDAZOLAM AUTOINJECTORS THAT HAVE RECEIVED EMERGENCY USE AUTHORIZATION (EUA) OR FDA APPROVAL FOR THE TREATMENT OF STATUS EPILEPTICUS SEIZURES IN ADULT AND PEDIATRIC POPULATIONS (2+ | CROSSJECT SA | Department of Health and Human Services | — | Jun 9, 2022 | $108,841,769 |
| 75A50123C00056 ADVANCE THE DEVELOPMENT OF POTENT, CROSS-REACTIVE MULTISPECIFIC ANTIBODIES FOR THE PREP COUNTERMEASURE OF COVID-19 AND SEASONAL AND HIGHLY PATHOGENIC AVIAN INFLUENZA. | MODEX THERAPEUTICS, INC | Department of Health and Human Services | MA | Sep 27, 2023 | $103,516,903 |
| 75A50123C00059 BARDA OTHER TRANSACTION PRIZE VEHICLE | LUMINARY LABS LLC | Department of Health and Human Services | NY | Sep 27, 2023 | $100,000,000 |
| 75A50120C00177 EO14042 TO DEVELOP MEDICAL COUNTERMEASURES (MCMS) THAT TREAT ANTIBIOTIC RESISTANT INFECTIONS. | VEDANTA BIOSCIENCES, INC. | Department of Health and Human Services | MA | Apr 2, 2026 | $99,146,088 |
Related records
Derived from awards these records share, ordered by how many.
Benchmarked as
Bought by
Performed in
Sources and method
Figures on this page are computed from public federal award records. Numbers are never estimated or generated; where a figure is withheld, the reason is stated rather than filled in.
Totals cover awards where the government recorded this NAICS code. Codes are taken as reported; awards are never reclassified into a different code.
- 1Awards are grouped by the NAICS code the government recorded on the award, taken from USAspending.gov and last refreshed Sep 26, 2026. Miscoded awards stay miscoded here; we do not reassign codes.